Clinical findings at the time of diagnosis of pneumonia in the learning and validation cohorts according to the presence of bacteria resistant to limited-spectrum antimicrobial therapy#
| Learning cohort | Validation cohort | |||||
| Susceptible | Resistant | p-value | Susceptible | Resistant | p-value | |
| Body temperature °C | 38.7±0.8 | 38.5±0.9 | 0.08 | 38.8±0.8 | 38.9±0.7 | 0.39 |
| White blood cells ×103 mL–1 | 12.9±6.1 | 12.3±5.4 | 0.56 | 12.7±6.4 | 13.1±6.3 | 0.73 |
| Lobes involved on chest radiograph | 1 (1–1) | 1 (1–1) | 0.39 | 1 (1–1) | 1 (1–1) | 0.97 |
| PaO2/FiO2 ratio | 186.3±77.7 | 196.7±92.2 | 0.44 | 201.5±86.5 | 226.7±101.0 | 0.18 |
| Time between hospitalisation and VAP onset days | 6 (4–8) | 8.5 (6–11) | <0.001 | 5 (4–8) | 11 (7–17) | <0.001 |
| Time between hospitalisation and VAP onset ≥ 10 days yes | 48 (15.1) | 24 (38.7) | <0.001 | 33 (15.6) | 24 (57.1) | <0.001 |
| Antimicrobial administration prior to VAP onset during current hospitalisation | ||||||
| Yes | 182 (57.4) | 59 (95.2) | <0.001 | 115 (55.0) | 40 (95.2) | <0.001 |
| Duration h | 12 (12–48) | 72 (48–120) | <0.001 | 12 (12–48) | 54 (18–132) | 0.007 |
| Antimicrobial prior to VAP onset ≥48 h yes | 50 (15.8) | 45 (72.6) | <0.001 | 39 (18.6) | 27 (64.3) | <0.001 |
Data are presented as mean±sd, median (interquartile range) or n (%), unless otherwise stated. PaO2: partial oxygen tension; FiO2: inspiratory oxygen fraction; VAP: ventilator-associated pneumonia. #: ampicillin/sulbactam, ceftriaxone or levofloxacin.